
0. Data and calendar

All values as of 6 AM ET / 3 AM PT, other than S&P500 close (4 PM ET / 1 PM PT).

All times are ET.
1. Heart disease: 3 drugs report positive clinical trials

VERVE-101's single-shot gene therapy reduced LDL-C (ābad cholesterolā) by up to 55% in a Phase 1 clinical trial.
Lepodisiran, a once-a-year shot, reduced lipoprotein(a), or Lp(a), by up to 94%, also in a Phase 1.
Wegovy reduced cardiovascular-related death by 20% in a 17.6K patient study. Wegovy is the branded name of semaglutide, already approved for weight loss.
Among the most sought-after corporate benefits.
2. Humane Ai Pin out only in 2024, product still not fully built out
Screenless smartphone that leverages OpenAIās APIs to answer questions, take pictures (video soon), text and call people, and ācatch me up.ā
Confirmed at $699 + $24/mo.
No App Store, but comes with Tidal for music, potential Slack, Microsoft, Google integration.
Our view: the future of computing is likely AR (more screens, not fewer ones) and Apple can copy voice computing features with Siri
Siri with Appleās new LLM can quickly obsolete the Ai Pin. Why not use my existing AirPods and talk to Siri, rather than pay $699 + $24/mo for a new device?
Not even founding investor Sam Altman is bullish on Humane: āThat will be up to customers to decide. Maybe itās a bridge too far, or maybe people are like, āThis is much better than my phone.ā Plenty of technology that looked like a sure bet ends up selling for 90 percent off at Best Buy.ā
3. Americans urge for a SECOND PASSPORT as the one-year countdown for the 2024 presidential election begins*
In search of a hedge against civil instability, more and more Americans turn towards a Citizenship-by-Investment program.
Having a Second Passport in 2023 is no longer a luxury, but a reasonable and necessary investment into your familyās safety.Ā See precise calculations here.
Watch this 5-minute webinar to learn everything you need to know about a Second Citizenship as an Insurance Policy and how you can obtain one.Ā
*Sponsored.








